B cell clonal expansion and cerebrospinal fluid (CSF) oligoclonal IgG bands are established features of the immune response in multiple sclerosis (MS). Clone-specific IgG1 monoclonal recombinant antibodies (rAbs) derived from MS patient CSF plasmablasts bound to conformational proteolipid protein 1 (PLP1) membrane complexes and, when injected into mouse brain with human complement, recapitulated histologic features of MS pathology: oligodendrocyte cell loss, complement deposition, and CD68+ phagocyte infiltration. Conformational PLP1 membrane epitopes were complex and governed by the local cholesterol and glycolipid microenvironment. Antibodies against conformational PLP1 membrane complexes targeted multiple surface epitopes, were enriched within the CSF compartment, and were detected in most MS patients but not in inflammatory and non-inflammatory neurologic controls. CSF PLP1 complex antibodies provide a pathogenic autoantibody biomarker specific for MS.
The application of personalized medicine to lung adenocarcinoma has resulted in new therapies based on specific oncogenic drivers that have improved patient outcomes. However, oncogene-defined subsets of patients exhibit a significant heterogeneity of response to these agents. Defining the factors that mediate the varied depth and duration of response are critical to developing new therapeutic strategies. While the examination of patient samples can provide important correlations, definitive mechanistic studies require the use of relevant preclinical models. Based on a large body of data, interactions between cancer cells and the surrounding tumor microenvironment, comprised of inflammatory, immune, and vascular cells, represent a critical determinant of therapeutic response. In this review, we focus on preclinical models that can be used to explore these interactions, identify new therapeutic targets, and test combination therapies. In particular, we will describe the use of implantable orthotopic immunocompetent models employing a panel of murine lung adenocarcinoma cell lines with oncogenic drivers common to human lung adenocarcinoma as a powerful system to develop new treatment approaches.
ENT blocks TrkB activation and proliferation of NSCLC TrkB+ cells lacking NTRK driving mutations. A, Western blot of NSCLC cells plated in phenol red–free media with 2.5% cs-FBS and pretreated for 2 hours with DMSO [vehicle (Veh)], ENT, LOXO101 (LOXO), cyclotraxin (Cyclo), or ANA12 (all drugs at 1 μmol/L), followed by stimulation with 50 ng/mL BDNF for 10 minutes. Tubulin served as a loading control. Densitometric values were calculated as phospho-TrkB/tubulin, total TrkB/tubulin, phospho-AKT/total AKT, and phospho-ERK/total ERK ratios and expressed relative to the Veh control group. B, Proliferation measured as percent confluency (mean ± SEM) using Incucyte live-cell imaging (n = 5 per treatment). Cells were plated in phenol red–free media with 2.5% cs-FBS and treated with Veh, 50 ng/mL BDNF alone, or BDNF combined with 1 μmol/L tyrosine kinase inhibitors. Data were analyzed by repeated-measures two-way ANOVA with post hoc multiple-comparison corrections.
ENT reduces NSCLC cell proliferation in coculture with astrocytes. Proliferation was quantified as green area (μm2) using live-cell imaging. A, H358; (B) H2030Br3; (C) Lu65; and (D) PC9Br3 cells were cultured either in starvation media (2% cs-FBS) alone or over a 100% confluent monolayer of primary mouse astrocytes, in combination with vehicle (Veh; DMSO) or ENT (1 μmol/L). Data were analyzed by repeated-measures two-way ANOVA followed by Fisher LSD test (n = 5 wells per treatment). P values shown are the adjusted P values for Veh vs. Veh + Ent or Veh-mAst vs. ENT-mAst at the last time point.